Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Total 13F shares
-
21,491,692
-
Share change
-
+439,021
-
Total reported value
-
$40,616,899
-
Put/Call ratio
-
3%
-
Price per share
-
$1.89
-
Number of holders
-
46
-
Value change
-
+$846,737
-
Number of buys
-
9
-
Number of sells
-
25
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q1 2023
As of 31 Mar 2023,
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
21,491,692 shares.
The largest 10 holders included
Bellevue Group AG, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., Boxer Capital, LLC, Artal Group S.A., EcoR1 Capital, LLC, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, BlackRock Inc., and CITADEL ADVISORS LLC.
This page lists
47
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.